About Vertical Bio
Vertical Bio was founded in 2021 in Basel, Switzerland, within the biotechnology sector. Therapeutics for lung cancer are developed, with a focus on non-small cell lung cancer (NSCLC). The lead candidate, VERT-002, is a monoclonal antibody designed to degrade c-MET, targeting cases involving MET mutations or amplification. Operations center on advancing this mechanism for potential NSCLC therapies.
- Headquarter Basel, Switzerland
- SectorsHealthcare
- Acquired by Pierre Fabre (Sep 2023)
- Investors
- Acquired byPierre Fabre
(Sep 2023)
Investors in Vertical Bio
Vertical Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pierre Fabre.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharma, dermo-cosmetics, OTC, and consumer health products are provided. | 1962 | pierre-fabre.com | Castres, France |
Investor details for Vertical Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vertical Bio
1 people are tracked at Vertical Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Olivier Bohuon | CEO | Leadership |
Complete people profiles for Vertical Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vertical Bio
2 dated milestones of Vertical Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Vertical Bio is founded.
- Exit Acquired by Pierre Fabre.
Similar companies to Vertical Bio
10 companies that operate in the same segment as Vertical Bio (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vertical Bio
Vertical Bio was founded in 2021.
Vertical Bio is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Olivier Bohuon is the current CEO of Vertical Bio.
Vertical Bio was founded in 2021 in Basel, Switzerland, within the biotechnology sector. Therapeutics for lung cancer are developed, with a focus on non-small cell lung cancer (NSCLC). The lead candidate, VERT-002, is a monoclonal antibody designed to degrade c-MET, targeting cases involving MET mutations or amplification. Operations center on advancing this mechanism for potential NSCLC therapies.
Vertical Bio has 1 investor. Key investors include Pierre Fabre.
Yes. Vertical Bio was acquired by Pierre Fabre in September 2023.